$TNGX
Tango Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024092274 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $11.61M $19.88M
YoY Change 8.15% 36.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.22M $10.77M
YoY Change 21.85% 17.43%
% of Gross Profit
Research & Development $33.26M $38.65M
YoY Change 22.52% 34.82%
% of Gross Profit
Depreciation & Amortization $622.0K $632.0K
YoY Change 1.97% 4.64%
% of Gross Profit
Operating Expenses $44.49M $49.43M
YoY Change 22.35% 30.6%
Operating Profit -$32.88M -$29.55M
YoY Change 28.3% 27.12%
Interest Expense $1.809M $2.071M
YoY Change -3.26% 42.83%
% of Operating Profit
Other Income/Expense, Net $3.765M $4.066M
YoY Change 11.19% 56.32%
Pretax Income -$29.11M -$25.49M
YoY Change 30.9% 23.44%
Income Tax $100.0K $100.0K
% Of Pretax Income
Net Earnings -$29.17M -$25.55M
YoY Change 31.01% 23.38%
Net Earnings / Revenue -251.29% -128.56%
Basic Earnings Per Share -$0.27 -$0.24
Diluted Earnings Per Share -$0.27 -$0.24
COMMON SHARES
Basic Shares Outstanding 107.1M 108.3M
Diluted Shares Outstanding 108.5M 108.3M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $293.3M $322.1M
YoY Change -18.51% 3.69%
Cash & Equivalents $53.15M $51.57M
Short-Term Investments $240.1M $270.5M
Other Short-Term Assets $7.537M $6.299M
YoY Change -32.1% -36.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $300.8M $328.4M
YoY Change -18.89% 2.45%
LONG-TERM ASSETS
Property, Plant & Equipment $8.590M $9.095M
YoY Change -16.28% -16.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.00K $10.00K
YoY Change -72.92% -16.67%
Total Long-Term Assets $51.60M $53.04M
YoY Change -9.94% -9.77%
TOTAL ASSETS
Total Short-Term Assets $300.8M $328.4M
Total Long-Term Assets $51.60M $53.04M
Total Assets $352.4M $381.5M
YoY Change -17.7% 0.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.112M $1.062M
YoY Change 44.94% -77.84%
Accrued Expenses $17.87M $19.14M
YoY Change 32.36% 27.65%
Deferred Revenue $15.60M $23.67M
YoY Change -42.37% -30.08%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.58M $43.87M
YoY Change -13.44% -18.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $85.66M $89.91M
YoY Change -20.83% -20.26%
Total Long-Term Liabilities $85.66M $89.91M
YoY Change -20.83% -20.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.58M $43.87M
Total Long-Term Liabilities $85.66M $89.91M
Total Liabilities $123.2M $133.8M
YoY Change -18.7% -19.6%
SHAREHOLDERS EQUITY
Retained Earnings -$463.9M -$434.7M
YoY Change 36.24% 36.61%
Common Stock $107.0K $107.0K
YoY Change 4.9% 21.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $229.2M $247.7M
YoY Change
Total Liabilities & Shareholders Equity $352.4M $381.5M
YoY Change -17.7% 0.56%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$29.17M -$25.55M
YoY Change 31.01% 23.38%
Depreciation, Depletion And Amortization $622.0K $632.0K
YoY Change 1.97% 4.64%
Cash From Operating Activities -$33.39M -$23.61M
YoY Change 7.23% -3.54%
INVESTING ACTIVITIES
Capital Expenditures $115.0K $320.0K
YoY Change 475.0% -51.81%
Acquisitions
YoY Change
Other Investing Activities $32.68M $13.02M
YoY Change -157.7% -60.96%
Cash From Investing Activities $32.57M $12.70M
YoY Change -157.47% -61.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.402M 1.311M
YoY Change -97.01% 123.72%
NET CHANGE
Cash From Operating Activities -33.39M -23.61M
Cash From Investing Activities 32.57M 12.70M
Cash From Financing Activities 2.402M 1.311M
Net Change In Cash 1.582M -9.597M
YoY Change -121.01% -209.06%
FREE CASH FLOW
Cash From Operating Activities -$33.39M -$23.61M
Capital Expenditures $115.0K $320.0K
Free Cash Flow -$33.51M -$23.93M
YoY Change 7.53% -4.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001819133
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2024Q2 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://www.tangotx.com/20240630#MarketableDebtSecuritiesMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://www.tangotx.com/20240630#MarketableDebtSecuritiesMember
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#MarketableSecuritiesCurrent
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#MarketableSecuritiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39485
dei Entity Registrant Name
EntityRegistrantName
TANGO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1195036
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Brookline Ave.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 901
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02215
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
320-4900
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TNGX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
107144465
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51566000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66385000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
270545000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
270500000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
856000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6299000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8797000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
328410000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
346538000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9095000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9908000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41371000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43508000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2567000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2567000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46000
CY2024Q2 us-gaap Assets
Assets
381453000
CY2023Q4 us-gaap Assets
Assets
402567000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1062000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2785000
CY2024Q2 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16774000
CY2023Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15401000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2364000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2082000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
23668000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
25670000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
43868000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45938000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35473000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36838000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
54439000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
66683000
CY2024Q2 us-gaap Liabilities
Liabilities
133780000
CY2023Q4 us-gaap Liabilities
Liabilities
149459000
CY2024Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107044240
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107044240
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102202759
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102202759
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
107000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
102000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
682621000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
624076000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-334000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
186000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-434721000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371256000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
247673000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
253108000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
381453000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
402567000
CY2024Q2 us-gaap Revenues
Revenues
19875000
CY2023Q2 us-gaap Revenues
Revenues
14598000
us-gaap Revenues
Revenues
26346000
us-gaap Revenues
Revenues
20364000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38654000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28671000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
76719000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56710000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10773000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9174000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21434000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17188000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
49427000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
37845000
us-gaap Operating Expenses
OperatingExpenses
98153000
us-gaap Operating Expenses
OperatingExpenses
73898000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29552000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23247000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71807000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53534000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2071000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1450000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4268000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2511000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1995000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1151000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4179000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2369000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4066000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2601000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8447000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4880000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25486000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20646000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63360000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48654000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
105000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25551000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20710000
us-gaap Net Income Loss
NetIncomeLoss
-63465000
us-gaap Net Income Loss
NetIncomeLoss
-48718000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108314279
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108314279
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88354590
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88354590
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108692822
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108692822
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88281368
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88281368
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25551000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20710000
us-gaap Net Income Loss
NetIncomeLoss
-63465000
us-gaap Net Income Loss
NetIncomeLoss
-48718000
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-77000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
684000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-520000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2188000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25628000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20026000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63985000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46530000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
253108000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1259000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41723000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6719000
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-443000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-37914000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
264452000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1311000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7538000
CY2024Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-77000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25551000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
247673000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
249476000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4219000
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1504000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28008000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
227264000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
586000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5121000
CY2023Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
684000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20710000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212945000
us-gaap Net Income Loss
NetIncomeLoss
-63465000
us-gaap Net Income Loss
NetIncomeLoss
-48718000
us-gaap Depreciation
Depreciation
1257000
us-gaap Depreciation
Depreciation
1185000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1850000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1781000
us-gaap Share Based Compensation
ShareBasedCompensation
14257000
us-gaap Share Based Compensation
ShareBasedCompensation
9340000
tngx Accretion On Marketable Securities1
AccretionOnMarketableSecurities1
-2575000
tngx Accretion On Marketable Securities1
AccretionOnMarketableSecurities1
-1769000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-33000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2498000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2462000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-36000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1724000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
340000
tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
1411000
tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-4245000
tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-796000
tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1461000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14246000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15364000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61464000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59380000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
515000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1284000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
170885000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
168833000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
168874000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
103311000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1496000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
64238000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41723000
tngx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options And Purchase Of Shares Under Employee Stock Purchase Plans
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndPurchaseOfSharesUnderEmployeeStockPurchasePlans
2570000
tngx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options And Purchase Of Shares Under Employee Stock Purchase Plans
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndPurchaseOfSharesUnderEmployeeStockPurchasePlans
659000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44293000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
659000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15675000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5517000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69808000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63958000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54133000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69475000
tngx Cash Paid For Leases
CashPaidForLeases
2314000
tngx Cash Paid For Leases
CashPaidForLeases
2982000
tngx Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification
RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification
497000
tngx Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification
RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification
-220000
tngx Obtain Return Of Asset By Recognition Of Lease Liability And Lease Modification
ObtainReturnOfAssetByRecognitionOfLeaseLiabilityAndLeaseModification
210000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3Y1M6D
CY2024Q2 tngx Fair Value Asset Level1 To Level2 Transfer Amount
FairValueAssetLevel1ToLevel2TransferAmount
0
CY2024Q2 tngx Fair Value Asset Level2 To Level1 Transfer Amount
FairValueAssetLevel2ToLevel1TransferAmount
0
CY2024Q2 tngx Fair Value Liabilities Level1 To Level2 Transfer Amounts
FairValueLiabilitiesLevel1ToLevel2TransferAmounts
0
CY2024Q2 tngx Fair Value Liabilities Level2 To Level1 Transfer Amounts
FairValueLiabilitiesLevel2ToLevel1TransferAmounts
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
270879000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
364000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
270545000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
270314000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
381000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
195000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
270500000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
205505000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
351000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4986000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
13000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
210491000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
364000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
59857000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
34000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
32164000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
161000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
92021000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
195000
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1400000
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1800000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16216000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15897000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7121000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5989000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9095000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9908000
us-gaap Depreciation
Depreciation
1300000
us-gaap Depreciation
Depreciation
1200000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5423000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7910000
CY2024Q2 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
9836000
CY2023Q4 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6204000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1515000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1287000
CY2024Q2 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16774000
CY2023Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15401000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51566000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66052000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2567000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3423000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54133000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69475000
CY2024Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7538000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5121000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14257000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9340000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16734960
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.21
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M29D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62640906
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4781209
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.64
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
507566
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
519507
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.68
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20489096
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M3D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42850128
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10076575
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M6D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
29469806
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25551000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20710000
us-gaap Net Income Loss
NetIncomeLoss
-63465000
us-gaap Net Income Loss
NetIncomeLoss
-48718000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108314279
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108314279
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88354590
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88354590
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108692822
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108692822
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88281368
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88281368
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
13196671
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21753803
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17683051
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 tngx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 tngx Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-092274-index-headers.html Edgar Link pending
0000950170-24-092274-index.html Edgar Link pending
0000950170-24-092274.txt Edgar Link pending
0000950170-24-092274-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tngx-20240630.htm Edgar Link pending
tngx-20240630.xsd Edgar Link pending
tngx-ex10_1.htm Edgar Link pending
tngx-ex31_1.htm Edgar Link pending
tngx-ex31_2.htm Edgar Link pending
tngx-ex32_1.htm Edgar Link pending
tngx-ex32_2.htm Edgar Link pending
tngx-ex3_1.htm Edgar Link pending
tngx-20240630_htm.xml Edgar Link completed